CalciMedica Files Prospectus to Offer Up to $25M Common Stock

What Happened

• On September 30, 2026, CalciMedica, Inc. filed a prospectus supplement with the SEC allowing the company to offer and sell, from time to time, up to $25,000,000 aggregate offering price of its common stock under its existing at-the-market (ATM) offering agreement with H.C. Wainwright & Co. The prospectus supplement is filed under CalciMedica’s shelf registration on Form S-3 (Reg. No. 333-293972).

Key Details

• Offering size: up to $25,000,000 aggregate offering price of common stock.
• Sales mechanism: at-the-market offerings under the Offering Agreement with H.C. Wainwright & Co. dated August 11, 2023.
• Shelf registration: Form S-3 originally filed March 3, 2026 and declared effective March 11, 2026.
• Legal opinion regarding the issuance is filed as Exhibit 5.1 to the Form 8-K.

Why It Matters

• The prospectus supplement gives CalciMedica the ability to raise capital by selling common stock over time through the ATM facility. The filing does not state whether or when shares will be sold or how proceeds will be used. If the company does sell shares under this program, it would increase the number of shares outstanding, which is the key investor consideration to monitor.